Like Novo Nordisk and Lilly, Metsera has been set up to develop a pipeline of weight-loss therapies based on GLP-1 receptor agonism, with a focus on peptides and peptide-antibody conjugates.

Metsera, however, is not a dividend stock and is, therefore, unattractive for income investors. Analysts are bullish on the biotech stock as the weight-loss drugs market is broadly expected to hit ...

Q1 2025 Management View Chirag Patel, Co-Founder and Co-CEO, highlighted Q1 2025 performance with revenues of $695 million ...

MET-097i achieved up to 11.3% mean placebo-adjusted weight loss at 12 weeks and exhibited a 380-hour (nearly 16-day) half-life and good tolerability. Metsera said the drug's profile is at least as ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Metsera is a clinical-stage biopharmaceutical ... targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera was founded in 2022 and is based in New York ...

April 18, 2024 Weight-loss drug developer Metsera raises $290 million in funding Weight-loss drug developer Metsera has raised $290 million in funding, led by biotech investor ARCH Venture ...